Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pharmaceutical industry. Novo Nordisk (NYSE: NVO) jumped out to an early lead with the immense popularity of its Ozempic and Wegovy (semaglutide), used to treat type 2 diabetes and obesity. However, a […]
Biology, Vol. 14, Pages 1650: GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects
Biology, Vol. 14, Pages 1650: GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects Biology doi: 10.3390/biology14121650 Authors: Milena Barać Jelena Roganović This review addresses the growing concern of oral side effects, particularly dry mouth, associated with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used […]
Nutrients, Vol. 17, Pages 3659: Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery?
Nutrients, Vol. 17, Pages 3659: Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients doi: 10.3390/nu17233659 Authors: Rhea Sibal G. Balamurugan Jasmine Langley Yitka Graham Kamal Mahawar Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people living with obesity and type 2 diabetes […]
Eli Lilly Hits $1 Trillion Milestone on GLP-1 Boom
Eli Lilly Hits $1 Trillion Milestone on GLP-1 Boom Eli Lilly and Company BATS:LLY DEXWireNews Eli Lilly & Co. (NYSE: LLY ) briefly crossed the $1 trillion market-cap threshold, becoming the first health-care company in history to reach the valuation. Shares traded around $1,059 as demand for its GLP-1 weight-loss and diabetes drugs exploded, driving […]
Managing weight
The Ozempic era should change how we think about self-control Oh, oh, oh, Ozempic! The catchy jingle from Novo Nordisk’s 2018 TV commercial helped to popularise Ozempic and cement its name as a generic term for an entire category of drugs, now prescribed to millions of people to treat diabetes and obesity. An earworm, however, […]
Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health
Post Content
Eli Lilly becomes first pharma firm to join $1 trillion club – Al Jazeera
Eli Lilly becomes first pharma firm to join $1 trillion club Al Jazeera Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value The New York Times Eli Lilly hits $1 trillion market value, a first for a health-care company CNBC Is GLP-1 the new AI? Drugmaker Eli Lilly joins the $1 trillion market-cap club. MarketWatch […]
Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s why
The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with pharmaceutical giants, announced Nov. 6, 2025, will reduce the monthly prices of these medications by hundreds of dollars.
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1
Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club – Investor’s Business Daily
Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club Investor’s Business Daily Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value The New York Times Is GLP-1 the new AI? Drugmaker Eli Lilly joins the $1 trillion market-cap club. MarketWatch Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts Yahoo […]